Last update:

Endocrinology news

Being obese can make you more likely to be unemployed

The effect of obesity on unemployment is more than twice as large as previously thought, finds a UK Biobank study of genetic evidence.

Semaglutide and other GLP-1 drugs not linked to risk of degenerative eye disease in adults with type 2 diabetes

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of medication that mimics the GLP-1 hormone—to lower blood sugar and support weight loss. Some research ...

Rise of GLP-1s raises long-term affordability questions

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. ...

What's driving the obesity pandemic?

New research presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico, (15–17 July) asks what is driving the obesity pandemic.

Muscles matter for diabetes risk, new study finds

A major new international study led by Curtin University has found diabetes risk is about more than body weight or obesity, revealing that muscle health also likely plays a major role in whether people develop the condition.

Weight‑loss jabs may create a new kind of yo‑yo dieting

For many people living with obesity, newer weight-loss medicines such as Wegovy and Mounjaro have been transformative. These drugs are often grouped under the label GLP-1 medicines because they mimic hormones released after ...

Fructose sends a weaker satiety signal to the brain than glucose

Researchers at the Monell Chemical Senses Center have found that common dietary sugars fructose and glucose, despite having the same number of calories, communicate with the brain through different gut–brain pathways, a difference ...

FDA approves rapid-acting inhaled insulin for children

The U.S. Food and Drug Administration has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 years and older who are living with type 1 or type 2 diabetes.

Researchers uncover new details in type 2 diabetes development

Researchers at the Ohio University Heritage College of Osteopathic Medicine have discovered new information about how type 2 diabetes develops and how future treatments may help protect insulin-producing cells in the pancreas. ...

Diabetes tied to higher tooth and implant loss over 10 years

Diabetes is associated with complications in multiple organs, including the oral cavity. As a group, people with type 1 or type 2 diabetes are at higher risk for oral diseases. According to a new thesis by dentist Anna Trullenque ...